The CXCR4 antibody (61) and antagonist AMD3100 (62) were reported to suppress osteosarcoma cell invasion and lung metastasis, and it revealed that CXCR4 may act as a therapeutic agent to inhibit osteosarcoma progression. This evidence concerns the gene CXCR4 and osteosarcoma.